Anaplastic Astrocytoma (AA)
3
0
0
2
Key Insights
Highlights
Success Rate
67% trial completion
Treatment Research
7 treatments under study, led by Surgery
Research Leaders
12 sponsors active, led by University of California, San Francisco
Related Conditions
Often studied with 12 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
33.3%
1 terminated out of 3 trials
66.7%
-19.9% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (3)
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Research Network
Common Treatments
- Surgery1
- Bevacizumab1
- Cv011
- 5aminolevulinic Acid Hydrochloride Gliolan1
- Aminolevulinic Acid Hydrochloride1
Active Sponsors
- University of California, San Francisco1
- Dana-Farber Cancer Institute1
- Alpheus Medical, Inc.1
- Genentech, Inc.1
- Massachusetts General Hospital1
Top Investigators
Department of Neurosurgery, University Hospital Münster, Münster, Germany, 48149
Memorial Sloan Kettering Cancer Center
Related Conditions
- Anaplastic Oligodendroglioma Ao3
- Brain Cancer1
- Glioblastoma Gbm1
- High Grade Glioma Glioblastoma Gbm1
- Anaplastic Mixed Gliomas1